Yes, the global trial took many years because patients lived a long time and the investigators were able to collect OS data from 94 sites worldwide…
I think what you mean to say is that everyone should do their own independent research about the DCVax global P3 and research the clinical investigators who designed and led the trial to verify that the trial that was conducted at 94 sites worldwide was in fact led by two clinical trial experts and that long term survivors who were trial participants are still alive today.
So many of these survivor stories are old news— research 2022 updates—some are GBM patients surpassing a decade or multiple decades—miraculous …
Dr. Linda Liau is a world-renowned neuro-oncologist, surgeon, and educator at UCLA where she is also the chair of the department of neurosurgery. As her paper on DCVax moves through the independent peer review process, it is interesting to note that she was once the editor-in-chief of a neuro-oncology medical journal: Dr. Liau has authored over 170 peer-reviewed research articles, along with several book chapters, and a textbook entitled Brain Tumor Immunotherapy. She is on the editorial boards of several scientific/medical journals and was the Editor-in-Chief of the Journal of Neuro-Oncology (2007–2017).
Across the pond from Dr. Liau, Dr. Ashkan was the chief investigator of the DCVax trial for patients in Europe. At King’s College in London, Ashkan is the lead clinician for neuro-oncology and the chair of the King’s Neurosciences Clinical Trial Unit. He is a world-renowned cancer trial expert. A few years ago, Professor Ashkan was named the UK Clinician of the Year by The Brain Tumour Charity. Additionally, Ashkan serves as an advisor to the U.K. government.
https://www.kcl.ac.uk/people/keyoumars-ashkan ————————————— https://soc-neuro-onc.org/ Autologous tumor lysate-loaded dendritic cell vaccination improves survival in patients with newly diagnosed and recurrent glioblastoma: survival results from a phase 3 trial Plenary Abstract Presenter: Linda M. M. Liau, MD PhD - University of California, Los Angeles
NWBO is special and the facts prove it, but false misleading opinions add no value. The fact that the OS data proved to be effective and there are patients who are alive is also proof. Deception, wrongful allegations, and other roadblocks have been invoked to sidetrack from the truth that NWBO is in fact moving forward in the right direction. Thanks for pointing this out.
Market Data 
Markets 
AI
